MoonLake AG reports Q1 2022 net loss of $15.9M; business combination with Helix closes raising $134.7M

MoonLake Immunotherapeutics

Net loss of $15.88M for three months ended March 31, 2022; accumulated deficit of $69.5M.
Cash of $8.8M; current liabilities exceeded current assets by $25.3M as of March 31, 2022.
Short-term loans of $30M from BVF and Cormorant repaid after Business Combination closed April 5, 2022.
Business Combination with Helix closed on April 5, 2022, raising $134.7M net of expenses.
Company is a clinical-stage biopharma focused on Nanobody sonelokimab (SLK) for inflammatory diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.